NCT07170761 (HEMOcalc) is a clinical trial in Vascular Disease, sponsored by Medical University of Graz.

Who is sponsoring NCT07170761?

NCT07170761 is sponsored by Medical University of Graz.

What condition does NCT07170761 study?

NCT07170761 studies Vascular Disease, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder.

Is NCT07170761 still recruiting?

NCT07170761 is currently active, enrolled. Last updated 5 March 2026.

Last reviewed 2026-03-05 · How we verify

NCT07170761: HEMOcalc

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarkers and Event Patterns of Vascular Disease in Hemodialysis

Active, enrolled Last updated 5 March 2026

What this trial tests

trial in Vascular Disease in 475 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 October 2022

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	Medical University of Graz
Status	Active, enrolled
Study type	OBSERVATIONAL
Enrollment	475
Start date	15 October 2022
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across Austria

Conditions studied

Vascular Disease — all drugs for Vascular Disease →
CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder — all drugs for CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder →

Sponsor

Medical University of Graz

Who can join

Adults 18 to 100, any sex, with Vascular Disease or CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parathyroid hormone (PTH) remains the central biomarker to classify CKD-metabolic bone disease (CKD-MBD) in hemodialysis patients. While PTH-values are known to be associated with adverse outcomes, interventional studies have failed to show a benefit of pharmacological modulation of PTH levels on hard clinical outcomes. To address this gap, the investigators explored alternative markers of bone metabolism, vascular calcification and inflammation in association to prospective event patterns.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Medical University of Graz trials

Trials by the same sponsor.

NCT07498244 — Collagen Fingerprinting for Stratification of Pulmonary Hypertension (PH) Patients · recruiting
NCT07492823 — Clinical Applicability of Liquid Biopsy in Chondrosarcoma · not yet recruiting
NCT07297615 — 3D Liver Volumetry · NA · not yet recruiting
NCT07588282 — The Effect of Psychoeducational Diagnosis Communication on Perception of Illness, Satisfaction, and Behavioral Intention · NA · recruiting
NCT07376096 — Liquid Biopsy in Germ Cell Tumors · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07170761 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Graz
Last refreshed: 5 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07170761.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing